| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Josefine Roemmler, Jochen Schopoh. Clinical experience with lanreotide for the treatment of acromegaly. Expert review of endocrinology & metabolism. vol 7. issue 2. 2019-11-20. PMID:30764005. |
this article reviews the use of lanreotide in the treatment of acromegaly and its advantages and disadvantages compared with other somatostatin analogues. |
2019-11-20 |
2023-08-13 |
Not clear |
| Nienke R Biermasz, Alberto M Pereira, Karen J Neelis, Ferdinand Roelfsema, Johannes A Romij. Role of radiotherapy in the management of acromegaly. Expert review of endocrinology & metabolism. vol 1. issue 3. 2019-11-20. PMID:30764082. |
active acromegaly can be treated effectively by transsphenoidal surgery, radiotherapy and medical treatment in the form of somatostatin analogs and growth hormone receptor antagonists. |
2019-11-20 |
2023-08-13 |
Not clear |
| Maria Caroline Alves Coelho, Marina Lipkin Vasquez, Luiz Eduardo Wildemberg, Mari C Vázquez-Borrego, Luciana Bitana, Aline Helen da Silva Camacho, Débora Silva, Liana Lumi Ogino, Nina Ventura, Leila Chimelli, Raul M Luque, Leandro Kasuki, Mônica R Gadelh. Molecular evidence and clinical importance of β-arrestins expression in patients with acromegaly. Journal of cellular and molecular medicine. vol 22. issue 4. 2019-11-08. PMID:29377493. |
β-arrestins seem to have a role in endocytosis and desensitization of somatostatin receptor subtype 2 (sst2) and could be associated with the responsiveness to somatostatin receptor ligands (srl) in patients with acromegaly. |
2019-11-08 |
2023-08-13 |
Not clear |
| Eva Venegas-Moreno, Mari C Vazquez-Borrego, Elena Dios, Noelia Gros-Herguido, Alvaro Flores-Martinez, Esther Rivero-Cortés, Ainara Madrazo-Atutxa, Miguel A Japón, Raúl M Luque, Justo P Castaño, David A Cano, Alfonso Soto-Moren. Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly. Journal of cellular and molecular medicine. vol 22. issue 3. 2019-10-21. PMID:29266696. |
association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly. |
2019-10-21 |
2023-08-13 |
human |
| Eva Venegas-Moreno, Mari C Vazquez-Borrego, Elena Dios, Noelia Gros-Herguido, Alvaro Flores-Martinez, Esther Rivero-Cortés, Ainara Madrazo-Atutxa, Miguel A Japón, Raúl M Luque, Justo P Castaño, David A Cano, Alfonso Soto-Moren. Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly. Journal of cellular and molecular medicine. vol 22. issue 3. 2019-10-21. PMID:29266696. |
somatostatin analogues (ssas) form the basis of medical therapy for acromegaly and are currently used as first-line treatment or as second-line therapy in patients undergoing unsuccessful surgery. |
2019-10-21 |
2023-08-13 |
human |
| Leandro Kasuki, Marilia Duarte Dalmolin, Luiz Eduardo Wildemberg, Mônica R Gadelh. Treatment escape reduces the effectiveness of cabergoline during long-term treatment of acromegaly in monotherapy or in association with first-generation somatostatin receptor ligands. Clinical endocrinology. vol 88. issue 6. 2019-09-30. PMID:29520805. |
treatment escape reduces the effectiveness of cabergoline during long-term treatment of acromegaly in monotherapy or in association with first-generation somatostatin receptor ligands. |
2019-09-30 |
2023-08-13 |
Not clear |
| Leandro Kasuki, Marilia Duarte Dalmolin, Luiz Eduardo Wildemberg, Mônica R Gadelh. Treatment escape reduces the effectiveness of cabergoline during long-term treatment of acromegaly in monotherapy or in association with first-generation somatostatin receptor ligands. Clinical endocrinology. vol 88. issue 6. 2019-09-30. PMID:29520805. |
few studies evaluated the use of cabergoline (cab) for acromegaly treatment in monotherapy or in combination with first-generation somatostatin receptor ligands (srls). |
2019-09-30 |
2023-08-13 |
Not clear |
| Aleksandra Jawiarczyk-Przybyłowska, Beata Wojtczak, James Whitworth, Krzysztof Sutkowski, Martin Bidlingmaier, Márta Korbonits, Marek Bolanowsk. Acromegaly associated with GIST, non-small cell lung carcinoma, clear cell renal carcinoma, multiple myeloma, medulla oblongata tumour, adrenal adenoma, and follicular thyroid nodules. Endokrynologia Polska. vol 70. issue 2. 2019-08-26. PMID:30742299. |
the patient refused pituitary surgery, and her acromegaly is currently well-controlled with somatostatin analogue therapy. |
2019-08-26 |
2023-08-13 |
Not clear |
| Burak Kocak, Emine Sebnem Durmaz, Pinar Kadioglu, Ozge Polat Korkmaz, Nil Comunoglu, Necmettin Tanriover, Naci Kocer, Civan Islak, Osman Kizilkili. Predicting response to somatostatin analogues in acromegaly: machine learning-based high-dimensional quantitative texture analysis on T2-weighted MRI. European radiology. vol 29. issue 6. 2019-08-05. PMID:30506213. |
predicting response to somatostatin analogues in acromegaly: machine learning-based high-dimensional quantitative texture analysis on t2-weighted mri. |
2019-08-05 |
2023-08-13 |
Not clear |
| Burak Kocak, Emine Sebnem Durmaz, Pinar Kadioglu, Ozge Polat Korkmaz, Nil Comunoglu, Necmettin Tanriover, Naci Kocer, Civan Islak, Osman Kizilkili. Predicting response to somatostatin analogues in acromegaly: machine learning-based high-dimensional quantitative texture analysis on T2-weighted MRI. European radiology. vol 29. issue 6. 2019-08-05. PMID:30506213. |
to investigate the value of machine learning (ml)-based high-dimensional quantitative texture analysis (qta) on t2-weighted magnetic resonance imaging (mri) in predicting response to somatostatin analogues (sa) in acromegaly patients with growth hormone (gh)-secreting pituitary macroadenoma, and to compare the qta with quantitative and qualitative t2-weighted relative signal intensity (rsi) and immunohistochemical evaluation. |
2019-08-05 |
2023-08-13 |
Not clear |
| b' Soraya Puglisi, Federica Spagnolo, Marta Ragonese, Salvatore Cannav\\xc3\\xb2, Francesco Ferra\\xc3\\xb. First report on persistent remission of acromegaly after withdrawal of long-term pegvisomant monotherapy. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 45. 2019-08-02. PMID:30772778.' |
the gh-receptor antagonist pegvisomant (peg) reduces peripheral igf-1 synthesis and is used to treat acromegaly patients resistant or intolerant to somatostatin analogues (ssa). |
2019-08-02 |
2023-08-13 |
Not clear |
| Michał Elbaum, Łukasz Mizera, Marek Bolanowsk. The real costs of acromegaly: analysis of different therapies. Endokrynologia Polska. vol 70. issue 1. 2019-07-12. PMID:30843180. |
in this paper a literature review was conducted for information related to costs of management of acromegaly and its associated comorbidities using pubmed.the majority of total costs represent pharmacological treatment, especially the most common somatostatin analogues (ssa) therapy. |
2019-07-12 |
2023-08-13 |
Not clear |
| Marco Losa, Carmine Antonio Donofrio, Marco Gemma, Lina Raffaella Barzaghi, Pietro Mortin. Pretreatment with somatostatin analogs does not affect the anesthesiologic management of patients with acromegaly. Pituitary. vol 22. issue 2. 2019-06-17. PMID:30826981. |
pretreatment with somatostatin analogs does not affect the anesthesiologic management of patients with acromegaly. |
2019-06-17 |
2023-08-13 |
Not clear |
| Ewa Orlewska, Renata Stępień, Katarzyna Orlewsk. Cost-effectiveness of somatostatin analogues in the treatment of acromegaly. Expert review of pharmacoeconomics & outcomes research. vol 19. issue 1. 2019-03-20. PMID:30122081. |
cost-effectiveness of somatostatin analogues in the treatment of acromegaly. |
2019-03-20 |
2023-08-13 |
Not clear |
| Ewa Orlewska, Renata Stępień, Katarzyna Orlewsk. Cost-effectiveness of somatostatin analogues in the treatment of acromegaly. Expert review of pharmacoeconomics & outcomes research. vol 19. issue 1. 2019-03-20. PMID:30122081. |
somatostatin analogues (ssas) are the largest contributor to the direct medical cost of acromegaly management worldwide. |
2019-03-20 |
2023-08-13 |
Not clear |
| Mark R Postma, Thalijn L C Wolters, Gerrit van den Berg, Antonius E van Herwaarden, Anneke C Muller Kobold, Wim J Sluiter, Margreet A Wagenmakers, Alfons C M van den Bergh, Bruce H R Wolffenbuttel, Ad R M M Hermus, Romana T Netea-Maier, André P van Bee. Postoperative use of somatostatin analogs and mortality in patients with acromegaly. European journal of endocrinology. vol 180. issue 1. 2019-03-05. PMID:30400068. |
postoperative use of somatostatin analogs and mortality in patients with acromegaly. |
2019-03-05 |
2023-08-13 |
Not clear |
| Mark R Postma, Thalijn L C Wolters, Gerrit van den Berg, Antonius E van Herwaarden, Anneke C Muller Kobold, Wim J Sluiter, Margreet A Wagenmakers, Alfons C M van den Bergh, Bruce H R Wolffenbuttel, Ad R M M Hermus, Romana T Netea-Maier, André P van Bee. Postoperative use of somatostatin analogs and mortality in patients with acromegaly. European journal of endocrinology. vol 180. issue 1. 2019-03-05. PMID:30400068. |
objective to assess the effect of somatostatin analogs (ssas) on mortality in relation to disease control of acromegaly after pituitary surgery. |
2019-03-05 |
2023-08-13 |
Not clear |
| Philippe J Eugster, Christina N Boyle, Sylvain Prod'hom, Erika Tarasco, Thierry Buclin, Thomas A Lutz, Alan G Harris, Eric Grouzman. Sensitive quantification of the somatostatin analog AP102 in plasma by ultra-high pressure liquid chromatography-tandem mass spectrometry and application to a pharmacokinetic study in rats. Drug testing and analysis. vol 10. issue 9. 2019-02-20. PMID:29745052. |
ap102 is a di-iodinated octapeptide somatostatin agonist (ssa) designed to treat acromegaly and neuroendocrine tumors. |
2019-02-20 |
2023-08-13 |
rat |
| F Albarel, F Castinetti, I Morange, N Guibert, T Graillon, H Dufour, T Bru. Pre-surgical medical treatment, a major prognostic factor for long-term remission in acromegaly. Pituitary. vol 21. issue 6. 2018-12-11. PMID:30367444. |
to determine whether pre-surgical medical treatment (psmt) using long-acting somatostatin analogues in acromegaly may improve long-term surgical outcome and to determine decision making criteria. |
2018-12-11 |
2023-08-13 |
Not clear |
| Christina M Lovato, Patricia L Kapsne. Analgesic effect of long-acting somatostatin receptor agonist pasireotide in a patient with acromegaly and intractable headaches. BMJ case reports. vol 2018. 2018-11-07. PMID:29925553. |
analgesic effect of long-acting somatostatin receptor agonist pasireotide in a patient with acromegaly and intractable headaches. |
2018-11-07 |
2023-08-13 |
Not clear |